Key result
Transatrial delivery of the Medtronic 3830 SelectSecure lead resulted in well-functioning pacing systems at midterm follow-up in 2 young adults with congenital heart disease.
Case Report (n=2)
Transatrial delivery of a 4-Fr lumenless pacing lead provides a viable pacing option for young adults with congenital heart disease and superior vena cava occlusion.
Answers are grounded in this paper and cite their sources.
Offers a potential pacing strategy for SVC occlusion in congenital heart disease; hypothesis-generating and requires prospective validation.
We report the technique of transatrial delivery of the Medtronic 3830 SelectSecure lead (Medtronic Inc., Minneapolis, MN, USA) for right ventricular endocardial pacing in two young adults with congenital heart disease who had multiple pacing lead failures and superior vena cava occlusion. The deflectable catheter delivery system used to position the SelectSecure lead provided the opportunity to map the right ventricular endocardial surface and determine the best available pacing site. At midterm follow-up, both systems are functioning well.
No takes yet. Share an insight, caveat, or question.
Fishberger et al. (2009) conducted a case report in Congenital heart disease with multiple pacing lead failures and superior vena cava occlusion (n=2). Transatrial delivery of the Medtronic 3830 SelectSecure lead was evaluated on System function. Transatrial delivery of the Medtronic 3830 SelectSecure lead resulted in well-functioning pacing systems at midterm follow-up in 2 young adults with congenital heart disease.
Synapse has enriched 10 related papers. Consider them for comparative context: